Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
- Study expected to enrol first participants during Q3 CY2024
- 预计在2024年第三季度招募首批参与者。
SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761.
2024年7月17日，澳洲悉尼（GLOBE NEWSWIRE）--临床阶段的生物技术公司Immutep Limited((ASX: IMm, NASDAQ:IMMP)（“Immutep”或“公司”）宣布已获得荷兰伦理和主管当局的监管批准，启动IMP761人体第一期临床研究。Immutep开发了针对癌症和自身免疫性疾病的新型LAG-3免疫疗法。
IMP761 is the world's first therapeutic LAG-3 agonist antibody and as such is uniquely positioned in the treatment landscape for autoimmune diseases. The immune checkpoint LAG-3 has been identified as a promising target for agonist immunotherapy to treat rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among other autoimmune diseases.1,2,3 IMP761 is designed to restore balance to the immune system by enhancing the "brake" function of LAG-3 to silence unregulated self-antigen-specific memory T cells. These T cells accumulate at disease sites and are the underlying cause of many autoimmune diseases.
IMP761是世界上第一个治疗性LAG-3激动剂抗体，因此在自身免疫性疾病的治疗领域中处于独特的位置。LAG-3免疫检查点已被确定为治疗类风湿性关节炎、1型糖尿病和多发性硬化等自身免疫性疾病的有前途的靶点。 IMP761的设计是通过增强LAG-3的“刹车”功能来恢复免疫系统的平衡，以沉默未受调节的自身抗原特异性记忆T细胞。这些T细胞在疾病部位积累，并是许多自身免疫性疾病的潜在原因。